Patent 10,137,095 (US): Scope and Claims Analysis for CBD in Lennox-Gastaut Drop Seizures (98% w/w CBD, ≤0.15% w/w THC, ~20 mg/kg/day)
US Drug Patent 10,137,095 claims specific method-of-treatment endpoints for Lennox-Gastaut syndrome (LGS) drop seizures using a defined CBD material (purity and THC cap) at a defined dose (~20 mg/kg/day), with optional add-on AED therapy and a specified AED set (with clobazam called out as a core combination in dependent claims).
What is the exact claim scope of US 10,137,095 for CBD in Lennox-Gastaut drop seizures?
Core claim concept: claim coverage is tied to (1) patient population (LGS), (2) seizure type (drop seizures), (3) active agent (CBD with defined purity and THC limit), (4) dose (~20 mg/kg/day), and (5) therapeutic intent (“reducing” frequency and/or “treating” drop seizures).
Claim 1 (and parallel independent claim set)
Independent claim 1 recites:
- Condition / indication: patient with Lennox-Gastaut syndrome
- Therapeutic endpoint: reducing drop seizure frequency
- Drug substance definition: administering cannabidiol (CBD) meeting:
- ≥ 98% (w/w) CBD
- ≤ 0.15% (w/w) Δ9-THC
- Dose: about 20 mg/kg/day
Meaning for infringement: To fall within claim 1, an accused regimen must administer CBD that matches the material spec (≥98% CBD and THC ≤0.15% w/w) and must dose it around 20 mg/kg/day in LGS drop seizure patients to achieve the reducing/treating effect.
Claim 5 (independent, endpoint switch)
Claim 5 recites:
- Condition: LGS
- Endpoint: treating drop seizures (not expressly “reducing frequency”)
- Same drug substance definition and same dose (~20 mg/kg/day)
Practical point: Claim 1 and claim 5 overlap heavily on compound definition and dosing; they mainly differ on the asserted clinical endpoint framing.
How do the dependent claims narrow the scope: adjunct AEDs and named drug lists?
Claim 2 and Claim 6 (broad “one or more AED” add-on)
- Claim 2 adds that CBD is administered in combination with one or more concomitant AEDs at a recommended therapeutic dose of the AED(s).
- Claim 6 is the same concept but depends from the “treating drop seizures” framework.
Scope effect: This expands infringement risk for combination regimens while keeping an “is within recommended dose” tether. “Recommended therapeutic dose” is a functional hook; it does not specify exact milligrams, but it requires the AED to be at a clinically standard dosing range.
Claim 3 and Claim 7 (limited AED set)
These claims narrow the AED list to a defined group:
- clobazam
- clonazepam
- levetiracetam
- topiramate
- stiripentol
- phenobarbital
- lacosamide
- valproic acid
- zonisamide
- perampanel
- fosphenytoin
Scope effect: Only combinations using one or more AEDs from the enumerated set fall under these dependent claims.
Claim 4 and Claim 8 (CBD + clobazam explicit dependent claims)
- Claim 4 depends on the “reducing drop seizure frequency” independent structure and requires CBD + clobazam with the same CBD spec and ~20 mg/kg/day.
- Claim 8 parallels Claim 4 for “treating drop seizures.”
Scope effect: This is the narrowest combination hook and is typically the most litigation-targeted scenario because clobazam is a common co-therapy in LGS drug regimens involving CBD.
What do the numeric limitations (98% CBD, ≤0.15% THC, ~20 mg/kg/day) do to claim breadth?
1) CBD purity and THC cap are “material identity” limitations
The claims require a CBD product meeting:
- ≥ 98% CBD (w/w)
- ≤ 0.15% Δ9-THC (w/w)
Consequence: A competitor using CBD with lower purity or higher THC carryover (even if still “CBD-enriched” or marketed as compliant) is outside the literal claim language unless it still meets the thresholds.
2) “About 20 mg/kg/day” creates a tolerated dosing window
“About” typically provides some elasticity around 20 mg/kg/day. That elasticity is not quantified in the claim text you provided, but it generally preserves coverage for regimens that land in the same clinical dosing range used to establish efficacy, as long as the dosing is sufficiently close.
Consequence for design-around:
- moving materially away from ~20 mg/kg/day is the most direct dosing carve-out approach,
- altering the material spec (CBD purity/THC cap) is the most direct formulation/carrier approach,
- switching indication context (not LGS drop seizures) is not viable if the patient still has the same target syndrome and seizure type.
What does “reducing drop seizure frequency” versus “treating drop seizures” change legally?
Functionally, both are method claims directed to therapeutic use. The distinction affects:
- proof framing (frequency reduction as an explicit primary endpoint versus general treatment benefit), and
- how claim construction might treat “reducing” as a measurable outcome tied to a regimen effect.
From an infringement posture, a regimen that clearly treats LGS drop seizures will typically also “reduce drop seizure frequency,” depending on how the clinical data is presented. The dual independent structure reduces the chance that a court narrows the endpoint to a specific clinical metric.
How many distinct inventive “threads” are inside US 10,137,095?
Based on your claim set, the landscape inside this single patent is structured around four separable claim threads:
- Method in LGS drop seizures (endpoint framing: reducing frequency or treating)
- Product/material limitation (CBD ≥98% and THC ≤0.15% w/w)
- Dose limitation (~20 mg/kg/day)
- Combination therapy (with AEDs broadly, then narrowed list, plus a clobazam-specific pair)
That modularity matters because an accused regimen can be assessed claim-by-claim:
- if any element fails (wrong material spec, wrong dosing, not LGS drop seizures, wrong endpoint context), the independent claim typically fails,
- dependent claims add further constraints (clobazam present, AED chosen from the enumerated list).
What patent landscape risks does this claim set create for CBD competitors (US generic or alternative CBD products)?
A) Formulation risks
To avoid infringement under the literal terms, a competitor would need to:
- use a CBD ingredient that does not satisfy ≥98% CBD or exceeds ≤0.15% THC,
- or adjust the administered CBD dosing such that it is not “about 20 mg/kg/day.”
This is a difficult design-around because many CBD-grade actives target high CBD content and low THC content; the differentiator is the exact compliance and manufacturing specs and the administered dose.
B) Dosing risks
A regimen at a different mg/kg/day can still face infringement arguments under “about,” depending on how courts interpret closeness. The claim’s “about” language is a litigation lever for both sides.
C) Labeling and clinical practice risks
Even if a competitor markets only “CBD” generally, infringement can be argued based on actual administration to LGS drop seizure patients at the claimed dose and material spec. Combination therapy with AEDs in recommended therapeutic dosing can bring additional dependent claim exposure.
D) AED co-therapy risks
Because clobazam is explicitly in Claims 4 and 8 and is likely common in LGS practice, any CBD regimen used with clobazam at the claimed dose and CBD spec faces direct dependent-claim risk.
Which claim elements are most “attackable” in litigation: material spec, dose, or population/endpoint?
Material spec (≥98% CBD; ≤0.15% THC)
This is often the most technically litigated element:
- testing methodology for CBD and Δ9-THC,
- batch-to-batch variability,
- regulatory/manufacturing certificates versus actual administered material.
If an accused product is documented or tested to fall outside either threshold, that can narrow exposure quickly.
Dose (“about 20 mg/kg/day”)
Dose infringement depends on:
- the mg/kg/day actually administered,
- titration schedule and duration,
- whether the regimen includes the claimed dosing “around 20.”
Population and endpoint (LGS + drop seizures)
If the intended or actual indication diverges (e.g., different seizure phenotype, different syndrome), that can be a strong defense. If the real-world use is still LGS drop seizures, defenses based on indication alone tend to be weaker.
Does this patent cover CBD + clobazam specifically or only as an optional add-on?
It covers both:
- Broadly, it covers CBD with one or more AEDs (Claims 2 and 6).
- Narrowly, it covers specific AED combos (Claims 3 and 7).
- It also covers CBD + clobazam specifically (Claims 4 and 8).
So the claim set is written to capture:
- standard-of-care combination regimens that include clobazam,
- and other AED combinations within the enumerated set.
What is the likely commercial “sweet spot” in scope: who will most likely practice the claims?
The most direct practice scenario is:
- an LGS drop seizures treatment regimen in US clinical use,
- using a high-purity CBD preparation with tightly controlled THC,
- dosed at about 20 mg/kg/day,
- co-administered with clobazam or other enumerated AEDs.
That typically maps to the competitive subset of CBD products used in LGS and dosed to match pivotal clinical protocols for drop seizure outcomes.
Key Takeaways
- US 10,137,095 is a method-of-use patent tied to LGS drop seizures and a specific CBD product definition (≥98% CBD; ≤0.15% Δ9-THC) administered at ~20 mg/kg/day.
- Two independent claims differ mainly by endpoint framing: reducing drop seizure frequency (Claim 1) versus treating drop seizures (Claim 5).
- Dependent claims expand infringement exposure for combination therapy with AEDs, first broadly (recommended therapeutic doses) then narrowly to a named AED list, with clobazam explicitly called out (Claims 4 and 8).
- The highest-likelihood infringement variables are (i) CBD purity/THC content, (ii) dosing closeness to ~20 mg/kg/day, and (iii) actual use in LGS drop seizure patients with co-administered AEDs.
FAQs
1) Does US 10,137,095 require clobazam for infringement?
No. Clobazam is explicitly required only in dependent Claims 4 and 8. Independent Claims 1 and 5 cover CBD alone at the specified CBD spec and dose in LGS drop seizures.
2) Can a competitor avoid the patent by using CBD with a THC level above 0.15% w/w?
If the administered CBD does not meet ≤0.15% (w/w) Δ9-THC, it falls outside the literal material limitations recited in the claims.
3) What dosing strategy is most relevant to design around “about 20 mg/kg/day”?
Moving materially away from the ~20 mg/kg/day range to a regimen not reasonably considered “about” 20 mg/kg/day is the most direct dosing design-around lever.
4) If a regimen reduces drop seizures but does not target “frequency,” does it still infringe?
Claim 5 covers “treating drop seizures” using the same CBD spec and dose, so seizure improvement framed as “treating” can still be within scope.
5) How do the AED-dependent claims affect real-world combination therapy risk?
If CBD is administered to LGS drop seizure patients at the claimed CBD spec and dose while co-administering AEDs at recommended therapeutic dosing, the claims can cover the combination, especially when the AED is in the enumerated list or when clobazam is used.
